24h
Current
Min
114.4
Max
114.95
Income | -83M 652M |
|---|---|
Sales | -25M 5.3B |
EPS | 2.07 |
Dividend yield | 1.34 |
Profit margin | 12.407 |
Recommendations | Buy |
|---|---|
12 Months Forecast | +22.55% upside |
Dividend yield Sector Avg | 1.34% 2.33% |
|---|---|
Next Earnings | 13 lis 2025 |
Market Cap | 98B |
|---|---|
Previous open | 115.25 |
Previous close | 114.95 |
By Acuity
19%
81%
29 / 371 Ranking in Healthcare
By Trading Central
Confidence
Strong Bearish Evidence
121.15 / 123.55 Support & Resistance
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
1 paź 2025, 08:54 UTC
Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site
DJ
Read
7 sie 2025, 05:43 UTC
Germany's Merck Raises Earnings Growth Guidance, But Turns Cautious on Sales
DJ
Read
16 paź 2025, 08:34 UTC
Merck KGaA's Cost Cutting Likely Led to Profitability Target Raise -- Market Talk
DJ
Read
15 paź 2025, 12:08 UTC
Merck KGaA Didn't Disclose Financial Details
DJ
Read
15 paź 2025, 12:07 UTC
Merck KGaA: JSR's Amsphere Protein A Resin Tech Complements Existing Biologics Portfolio
DJ
Read
15 paź 2025, 12:07 UTC
Merck KGaA: Unit is Based in Belgium, Has 50+ Employees
DJ
Read
15 paź 2025, 12:06 UTC
Merck KGaA: Deal Will Strengthen Position in Bioprocessing Market
DJ
Read
15 paź 2025, 12:05 UTC
Merck KGaA: Definitive Agreement Signed Today
DJ
Read
15 paź 2025, 12:05 UTC
Merck KGaA: Transaction Expected to Close by End of 2Q 2026
DJ
Read
15 paź 2025, 12:04 UTC
Merck KGaA to Buy Chromatography Business JSR Life Sciences
DJ
Read
15 paź 2025, 12:03 UTC
Merck KGaA to Buy Chromatography Business of JSR Life Sciences
DJ
Read
7 sie 2025, 08:04 UTC
Germany's Merck Misses Expectations on Weaker Electronics Performance -- Market Talk
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA Had Seen 2025 Group Ebitda Before Exceptional Items of EUR5.8B-EUR6.4B
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA Had Guided for 2025 Group Sales of EUR20.9B-EUR22.4B
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA Had Seen 2025 Organic Growth in Ebitda Before Exceptional Items at 2%-7%
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA Had Guided for 2025 Organic Sales Growth at 2%-6%
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA Now Sees 2025 Group Ebitda Before Exceptional Items of EUR5.9B-EUR6.3B
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA Now Sees 2025 Organic Growth in Ebitda Before Exceptional Items at 4%-8%
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA Cuts 2025 View To Sales EUR20.5B-EUR21.7B
DJ
Read
7 sie 2025, 05:00 UTC
Analysts Saw Merck KGaA 2Q Sales at EUR5.32B
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA Now Expects 2025 Organic Sales Growth at 2%-5%
DJ
Read
7 sie 2025, 05:00 UTC
Analysts Saw Merck KGaA 2Q Ebitda Before Exceptional Items at EUR1.52B
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA Says It Faced Strong Currency Headwinds
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA Adjusts 2025 View
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA Raises 2025 Guidance for Organic Growth in Ebitda Before Exceptional Items
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA Narrows 2025 Organic Sales Growth Guidance
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA 2Q EBITDA EUR1.35B
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA 2Q After-Tax Profit EUR655M
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA 2Q Sales EUR5.255B
DJ
Read
7 sie 2025, 05:00 UTC
Merck KGaA 2Q Ebitda Before Exceptional Items EUR1.46B
DJ
Read
By TipRanks
12 Months Forecast
Average 140.99 EUR 22.55%
High 182 EUR
Low 115.9 EUR
Based on 9 Wall Street analysts offering 12 month price targets forMerck KGaA - Dist in the last 3 months.
By TipRanks
Buy
9 ratings
6
Buy
3
Hold
0
Sell
Based on 9 analysts giving stock ratings to Merck KGaA - Dist in the past 3 months.
By Trading Central
Short Term
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Intermediate Term
Neutral Evidence
The bullish and bearish events are balanced.
Long Term
Bearish Evidence
All events are bearish.
By Acuity
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$